NDA 202088 · Citius Pharms
Suprenza
Phentermine Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 18, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Mar 27, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
73
8 Phase 3, 5 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2012 Original approval · Efficacy
- Jun 13, 2011 Original approval · Type 5 - New Formulation or New Manufacturer LabelSummary ReviewLabel
3 products under this application
- SUPRENZA · PHENTERMINE HYDROCHLORIDE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
- SUPRENZA · PHENTERMINE HYDROCHLORIDE 37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
- SUPRENZA · PHENTERMINE HYDROCHLORIDE 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Phentermine" as an intervention, any sponsor and status, largest first.
- A Toolbox Approach to Obesity Treatment in Primary CarePivotal-lookingCompleted
Denver Health and Hospital AuthorityAcademic, hospital or other
NCT01922934 · 4,730 participants · Start Jan 2014 · Primary completion Aug 2016
Drug: Obesity pharmacotherapy · For: Obesity
Sites: Denver, Colorado
- Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid ConditionsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00553787 · 2,487 participants · Start Nov 2007 · Primary completion Jun 2009
Drug: VI-0521; VI-0521 and 1 more · For: Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Ridgefield, Connecticut; New York, New York · 6 sites in all
- Study of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00554216 · 1,267 participants · Start Nov 2007 · Primary completion May 2009
Drug: VI-0521; VI-0521 and 1 more · For: Obesity
Sites: San Diego, California; Ridgefield, Connecticut; Durham, North Carolina · 5 sites in all
- Long-term Effectiveness of the Antiobesity Medication PhenterminePivotal-lookingCompleted
Wake Forest University Health SciencesAcademic, hospital or other
NCT05176626 · 870 participants · Start Jun 30, 2022 · Primary completion Sep 30, 2026
Drug: Phentermine Hydrochloride 8 MG · For: Obesity; Obesity; Drug; Lifestyle, Healthy
Sites: Los Angeles, California; Saint Louis Park, Minnesota; Winston-Salem, North Carolina · 4 sites in all
- A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00563368 · 756 participants · Start Dec 2007 · Primary completion Sep 2008
Drug: VI-0521; VI-0521 and 5 more · For: Obesity
Sites: Durham, North Carolina; Philadelphia, Pennsylvania
- A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)Pivotal-lookingCompleted
VIVUS LLCIndustry
NCT00796367 · 676 participants · Start Dec 2008 · Primary completion Jun 2010
Drug: VI-0521; Placebo and 1 more · For: Obesity
- Intermittent Phentermine for Obesity and Body CompositionPivotal-lookingCompleted
OSCAR MANUEL TORRES FALCONAcademic, hospital or other
NCT07870668 · 600 participants · Start Mar 1, 2024 · Primary completion Jan 15, 2026
Drug: Phentermine 15 MG; Phentermine 30 mg and 1 more · For: Obesity & Overweight
Sites: León, Mexico
- A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese SubjectsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT05215418 · 565 participants · Start Jan 25, 2022 · Primary completion Apr 11, 2023
Drug: VI-0521; Phentermine and 1 more · For: Blood Pressure
Sites: Anniston, Alabama; Mobile, Alabama; Lincoln, California · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
McGowan B, Ciudin A, Baker JL, et al. · Nat Med 2025 · Systematic Review, Network Meta-Analysis
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong K, Shi Q, Xie X, et al. · BMJ 2026 · Systematic Review, Network Meta-Analysis
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Elkind-Hirsch KE, Chappell N, Seidemann E, et al. · J Clin Endocrinol Metab 2021 · Equivalence Trial, Randomized Controlled Trial
- Obesity in adults.
Delaet D, Schauer D · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Citius Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.